- Gilead’s coronavirus treatment redemsivir was found to reduce recovery time in patients by several days
- Redemsivir and other drug treatments could serve as stopgap measures until a proper vaccine is ready and approved
- The Trump administration and Congress re-entered negotiations about a stimulus package to help a U.S. economy hit hard by the pandemic
Final results from Gilead Sciences’ latest remdesivir trial showed the antiviral drug was effective in treating coronavirus patients and cutting recovery time by at least a week.
Gilead’s CEO said, given the positive results, the company was ready for mass production and distribution of the drug.
As of Friday, Johns Hopkins said the U.S. has over 7.6 million confirmed cases of coronavirus and 212,805 reported deaths from it. The latest trial was conducted for nearly a month and involved over 1,062 patients hospitalized for coronavirus. Half of the patients were given remdesivir while the